Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Bayer Revving Up Cell Therapy Drive with First Focus on Parkinson’s, Japan Biz Also Eyed: R&D Chief
July 10, 2020
- Yoshiaki Aono to Be Promoted to Chairman and President of Nippon BI in September
July 10, 2020
- Maruho’s Nemolizumab Hits Primary Goal in Japanese PIII for Itching in Atopic Dermatitis
July 10, 2020
- Xofluza Effective for Post-Exposure Prophylaxis of Influenza: Japan PIII
July 10, 2020
- Astex’s Inqovi Gets Approval in US, Canada: Otsuka
July 9, 2020
- Eisai Files Tazemetostat for Follicular Lymphoma in Japan
July 9, 2020
- Eisai’s Sleep Inducer Dayvigo Accepted in Hong Kong
July 9, 2020
- Lenvima-Keytruda Combo’s 1st Line HCC Bid Nixed in US after Rival Nod
July 9, 2020
- Patient Numbers Remain Down at Over 60% of Hospitals Even after Emergency Lifted: Survey
July 9, 2020
- Aducanumab Filing Completed in US; Talks with Japan/EU Regulators Ongoing
July 9, 2020
- Medicago, GSK Team Up to Develop Adjuvanted COVID-19 Vaccine, PI to Commence in Mid-July
July 9, 2020
- GSK in Quest for Best COVID-19 Vaccine, Not the First: Japan Chief Lirette
July 8, 2020
- Sales Rep Promotions in May Tank 67% YOY: Intage
July 8, 2020
- Japan Ethical Drug Sales Slide 12.0% in May: Crecon
July 8, 2020
- EU Regulators Accept Enhertu for Accelerated Review for HER2-Positive Breast Cancer
July 8, 2020
- Sunovion’s Bipolar Depression Med Fails to Show Statistically Significant Improvement in PII
July 8, 2020
- Keytruda Snatches Back Top Crown in June Drug Sales Ranking: Encise
July 7, 2020
- Amgen Takes Over Japan MA for Otezla
July 7, 2020
- Eisai Launches Dayvigo, Fycompa Fine Granules in Japan
July 7, 2020
- Ono to Fight Prof. Honjo’s Lawsuit over Opdivo Royalties
July 7, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…